» Articles » PMID: 25669969

MYC is a Critical Target of FBXW7

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Feb 12
PMID 25669969
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

MYC deregulation is a driver of many human cancers. Altering the balance of MYC protein levels at the level of transcription, protein stability, or turnover is sufficient to transform cells to a tumorigenic phenotype. While direct targeting of MYC is difficult, specific genetic vulnerabilities of MYC-deregulated cells could be exploited to selectively inhibit their growth. Using a genome-wide shRNA screen, we identified 78 candidate genes, which are required for survival of human mammary epithelial cells with elevated MYC levels. Among the candidates, we validated and characterized FBXW7, a component of the SCF-like ubiquitin ligase complex that targets MYC for proteasomal degradation. Down-regulation of FBXW7 leads to synergistic accumulation of cellular and active chromatin-bound MYC, while protein levels of other FBXW7 targets appear unaffected. Over a four-week time course, continuous FBXW7 down-regulation and MYC activation together cause an accumulation of cells in S-phase and G2/M-phase of the cell cycle. Under these conditions, we also observe elevated chromatin-bound levels of CDC45, suggesting increased DNA replication stress. Consistent with these results, FBXW7 down-regulation alone decreases the survival of T47D breast cancer cells. These results establish that FBXW7 down-regulation is synthetic lethal with MYC, and that MYC is a critical target of FBXW7 in breast epithelial cells.

Citing Articles

Molecular and Pathological Features of Paediatric High-Grade Gliomas.

Blasco-Santana L, Colmenero I Int J Mol Sci. 2024; 25(15).

PMID: 39126064 PMC: 11312892. DOI: 10.3390/ijms25158498.


A microdeletion event at 19q13.43 in IDH-mutant astrocytomas is strongly correlated with MYC overexpression.

Ulgen E, Gerlevik U, Gerlevik S, Oktay Y, Sezerman O, Turcan S Acta Neuropathol Commun. 2024; 12(1):95.

PMID: 38877600 PMC: 11177509. DOI: 10.1186/s40478-024-01811-1.


Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality.

Lin P, Lourenco C, Cruickshank J, Palomero L, van Leeuwen J, Tong A Cancer Res. 2023; 83(24):4015-4029.

PMID: 37987734 PMC: 10722143. DOI: 10.1158/0008-5472.CAN-22-2948.


Inhibitors Targeting the F-BOX Proteins.

Naseem Y, Zhang C, Zhou X, Dong J, Xie J, Zhang H Cell Biochem Biophys. 2023; 81(4):577-597.

PMID: 37624574 DOI: 10.1007/s12013-023-01160-1.


Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas.

Seligson N, Tang J, Jin D, Bennett M, Elvin J, Graim K NPJ Precis Oncol. 2022; 6(1):29.

PMID: 35468996 PMC: 9038792. DOI: 10.1038/s41698-022-00271-x.


References
1.
Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H . Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004; 23(10):2116-25. PMC: 424394. DOI: 10.1038/sj.emboj.7600217. View

2.
Liu J, Levens D . Making myc. Curr Top Microbiol Immunol. 2006; 302:1-32. DOI: 10.1007/3-540-32952-8_1. View

3.
Cermelli S, Jang I, Bernard B, Grandori C . Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harb Perspect Med. 2014; 4(3). PMC: 3935389. DOI: 10.1101/cshperspect.a014209. View

4.
Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher D . Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A. 2003; 100(17):9974-9. PMC: 187906. DOI: 10.1073/pnas.1732638100. View

5.
Adhikary S, Eilers M . Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005; 6(8):635-45. DOI: 10.1038/nrm1703. View